D

Duopharma Biotech Bhd
KLSE:DPHARMA

Watchlist Manager
Duopharma Biotech Bhd
KLSE:DPHARMA
Watchlist
Price: 1.26 MYR 0.8% Market Closed
Market Cap: 1.2B MYR
Have any thoughts about
Duopharma Biotech Bhd?
Write Note

Intrinsic Value

The intrinsic value of one DPHARMA stock under the Base Case scenario is 1.69 MYR. Compared to the current market price of 1.26 MYR, Duopharma Biotech Bhd is Undervalued by 25%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

DPHARMA Intrinsic Value
1.69 MYR
Undervaluation 25%
Intrinsic Value
Price
D
Worst Case
Base Case
Best Case

Valuation History
Duopharma Biotech Bhd

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Valuation History Unavailable

Historical valuation for DPHARMA cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
How do you feel about DPHARMA?
Bearish
Neutral
Bullish

Fundamental Analysis

1.26 MYR
+0.8%
+0.8%
Benchmark
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Duopharma Biotech Bhd
MY
Pharmaceuticals
Market Cap
1.2B MYR
IPO
Jul 18, 2002
Employees
1 524
Malaysia
Market Cap
1.2B MYR
Industry
Pharmaceuticals
IPO
Jul 18, 2002
Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about Duopharma Biotech Bhd

Provide an overview of the primary business activities
of Duopharma Biotech Bhd.

What unique competitive advantages
does Duopharma Biotech Bhd hold over its rivals?

What risks and challenges
does Duopharma Biotech Bhd face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Duopharma Biotech Bhd.

Provide P/S
for Duopharma Biotech Bhd.

Provide P/E
for Duopharma Biotech Bhd.

Provide P/OCF
for Duopharma Biotech Bhd.

Provide P/FCFE
for Duopharma Biotech Bhd.

Provide P/B
for Duopharma Biotech Bhd.

Provide EV/S
for Duopharma Biotech Bhd.

Provide EV/GP
for Duopharma Biotech Bhd.

Provide EV/EBITDA
for Duopharma Biotech Bhd.

Provide EV/EBIT
for Duopharma Biotech Bhd.

Provide EV/OCF
for Duopharma Biotech Bhd.

Provide EV/FCFF
for Duopharma Biotech Bhd.

Provide EV/IC
for Duopharma Biotech Bhd.

Show me price targets
for Duopharma Biotech Bhd made by professional analysts.

What are the Revenue projections
for Duopharma Biotech Bhd?

How accurate were the past Revenue estimates
for Duopharma Biotech Bhd?

What are the Net Income projections
for Duopharma Biotech Bhd?

How accurate were the past Net Income estimates
for Duopharma Biotech Bhd?

What are the EPS projections
for Duopharma Biotech Bhd?

How accurate were the past EPS estimates
for Duopharma Biotech Bhd?

What are the EBIT projections
for Duopharma Biotech Bhd?

How accurate were the past EBIT estimates
for Duopharma Biotech Bhd?

Compare the revenue forecasts
for Duopharma Biotech Bhd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Duopharma Biotech Bhd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Duopharma Biotech Bhd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Duopharma Biotech Bhd compared to its peers.

Compare the P/E ratios
of Duopharma Biotech Bhd against its peers.

Discuss the investment returns and shareholder value creation
comparing Duopharma Biotech Bhd with its peers.

Analyze the financial leverage
of Duopharma Biotech Bhd compared to its main competitors.

Show all profitability ratios
for Duopharma Biotech Bhd.

Provide ROE
for Duopharma Biotech Bhd.

Provide ROA
for Duopharma Biotech Bhd.

Provide ROIC
for Duopharma Biotech Bhd.

Provide ROCE
for Duopharma Biotech Bhd.

Provide Gross Margin
for Duopharma Biotech Bhd.

Provide Operating Margin
for Duopharma Biotech Bhd.

Provide Net Margin
for Duopharma Biotech Bhd.

Provide FCF Margin
for Duopharma Biotech Bhd.

Show all solvency ratios
for Duopharma Biotech Bhd.

Provide D/E Ratio
for Duopharma Biotech Bhd.

Provide D/A Ratio
for Duopharma Biotech Bhd.

Provide Interest Coverage Ratio
for Duopharma Biotech Bhd.

Provide Altman Z-Score Ratio
for Duopharma Biotech Bhd.

Provide Quick Ratio
for Duopharma Biotech Bhd.

Provide Current Ratio
for Duopharma Biotech Bhd.

Provide Cash Ratio
for Duopharma Biotech Bhd.

What is the historical Revenue growth
over the last 5 years for Duopharma Biotech Bhd?

What is the historical Net Income growth
over the last 5 years for Duopharma Biotech Bhd?

What is the current Free Cash Flow
of Duopharma Biotech Bhd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Duopharma Biotech Bhd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Duopharma Biotech Bhd

Current Assets 725.3m
Cash & Short-Term Investments 260.4m
Receivables 244.9m
Other Current Assets 220m
Non-Current Assets 627.6m
Long-Term Investments 25.3m
PP&E 557.9m
Intangibles 37m
Other Non-Current Assets 7.5m
Current Liabilities 167.6m
Accounts Payable 109.8m
Other Current Liabilities 57.7m
Non-Current Liabilities 489.3m
Long-Term Debt 468.7m
Other Non-Current Liabilities 20.6m
Efficiency

Earnings Waterfall
Duopharma Biotech Bhd

Revenue
787.5m MYR
Cost of Revenue
-506.1m MYR
Gross Profit
281.4m MYR
Operating Expenses
-191.6m MYR
Operating Income
89.8m MYR
Other Expenses
-33.8m MYR
Net Income
56.1m MYR

Free Cash Flow Analysis
Duopharma Biotech Bhd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

DPHARMA Profitability Score
Profitability Due Diligence

Duopharma Biotech Bhd's profitability score is 51/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive 3-Years Revenue Growth
Positive Revenue Growth Forecast
Positive 1-Year Revenue Growth
51/100
Profitability
Score

Duopharma Biotech Bhd's profitability score is 51/100. The higher the profitability score, the more profitable the company is.

DPHARMA Solvency Score
Solvency Due Diligence

Duopharma Biotech Bhd's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Average Altman Z-Score
53/100
Solvency
Score

Duopharma Biotech Bhd's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

DPHARMA Price Targets Summary
Duopharma Biotech Bhd

Wall Street analysts forecast DPHARMA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DPHARMA is 1.47 MYR with a low forecast of 1.35 MYR and a high forecast of 1.63 MYR.

Lowest
Price Target
1.35 MYR
7% Upside
Average
Price Target
1.47 MYR
17% Upside
Highest
Price Target
1.63 MYR
29% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for DPHARMA?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for DPHARMA is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

See Also

Discover More
What is the Intrinsic Value of one DPHARMA stock?

The intrinsic value of one DPHARMA stock under the Base Case scenario is 1.69 MYR.

Is DPHARMA stock undervalued or overvalued?

Compared to the current market price of 1.26 MYR, Duopharma Biotech Bhd is Undervalued by 25%.

Back to Top